Five conditions a pharma company needs before it buys
Understanding the real buyer — and building your equity story around their decision criteria — is the most important repositioning a founder can make.
There is a question that most biotech founders never ask before walking into an investor meeting. It is not about the science, the market size, or the competitive landscape. It is simpler and more fundamental than any of those.
Who is the real buyer?
Not the VC sitting across the table. The VC is an intermediary. Their return depends entirely on a third party — typically a large pharmaceutical or medtech company — being willing to acquire the asset at a significant premium. If your narrative does not address that third party's decision criteria, the VC has no visible exit to model. And without a visible exit, there is no investment thesis to fund.
This is the structural confusion at the heart of most biotech fundraising. Founders pitch VCs as though VCs were the end buyer. They are not.
Understanding the real buyer, and building your equity story around their decision criteria, is the most important repositioning a founder can make.
How pharma actually evaluates an asset
When a pharmaceutical company's business development team evaluates an early-stage asset, they use a standard tool: risk-adjusted net present value. They estimate future revenues, multiply by the cumulative probability of reaching market at each clinical stage, and compare the result against the acquisition price being asked.
The founder's task is not to tell a compelling story. It is to move that probability number to the point where the acquisition becomes financially rational for a specific acquirer.
This requires understanding exactly what conditions must be true for that calculation to work in the asset's favour. And those conditions are not vague. They are specific, threshold-based, and largely non-negotiable.
There are five of them.
The five threshold conditions
The observed efficacy is reproducible, not an artefact of a small sample or a favourable patient selection. The effect size is clinically meaningful, not merely statistically significant. The safety profile is compatible with the treatment duration the indication requires. And the primary endpoint is one that regulators will accept and payers will reimburse.
A clinical result that impresses a scientific audience but cannot be translated into a reimbursable health outcome is commercially worthless. The question is not whether the drug works. It is whether it works in a way that someone will pay for.
The intellectual property protection is solid in the markets that generate the economics, principally the United States and Europe. The composition of matter is protected where possible. The patent expiry date leaves sufficient commercial runway to justify the acquisition premium. And there are no obvious freedom-to-operate issues that a competitor could exploit.
A weak patent position does not necessarily kill a deal, but it dramatically changes the valuation and the terms. Founders who have not stress-tested their IP position before approaching pharma are walking into a negotiation they are not prepared for.
The chemistry, manufacturing, and controls are stable, scalable, and not dependent on heroic effort to reproduce batch to batch. For small molecules, a reliable synthesis route with acceptable yields. For biologics, a manufacturing process that can be transferred to a contract manufacturer. For cell and gene therapies, demonstrating that the complexity is understood and manageable.
CMC is the uncertainty that founders most frequently underestimate — and the one that most frequently derails deals at late diligence. A pharma company acquiring an asset is acquiring a manufacturing process as much as a molecule.
The pathway to approval is clear and precedented. The regulatory agency has provided guidance, or comparable products have navigated a similar path. The clinical programme has been designed with the endpoint and the label in mind, not just the biology.
A regulatory risk that cannot be quantified is a risk that cannot be priced. Assets that require genuinely novel regulatory pathways carry uncertainty that is difficult to model and therefore difficult to pay for.
The asset addresses a gap in the acquirer's portfolio, strengthens a therapeutic area franchise, or protects against an imminent patent cliff. The timing aligns with the acquirer's strategic cycle. And the indication and modality are ones the acquirer has the commercial infrastructure to exploit.
Pipeline fit is not about whether the asset is good. It is about whether it is good for this buyer, at this moment. A perfectly good asset in a therapeutic area the acquirer has just decided to exit will not be acquired, regardless of its clinical merits.
These are threshold conditions, not preferences
The critical thing to understand about these five conditions is that they are not a scoring rubric. An asset does not pass if it scores well on four out of five. Each condition is a threshold. An asset that fails any single one of them does not advance past the first filter, regardless of how well it performs on the others.
The weakest link determines fundability
Improving clinical data when the IP position is weak does not make the asset more fundable. It makes it more impressive but still unfundable. The weakest condition, not the strongest, determines the asset's fundability at any given moment.
The uncertainty map, discussed in a previous article, is the tool for identifying which condition is currently weakest. But the map is only useful if you are mapping against the right destination. And the destination is a pharma acquisition decision, not a VC term sheet.
The question most founders cannot answer
Before any investor meeting, a founder should be able to answer three questions without hesitation.
Which specific company would acquire this asset?
Not a category of company. A named company, with a named therapeutic area franchise, and a named gap in their pipeline that this asset addresses.
What business problem does this asset solve for that company?
Not the clinical problem it solves for patients. The strategic problem it solves for the acquirer. Is it a patent cliff defence? A franchise extension? An entry into a new indication? The answer determines the acquisition rationale, and the acquisition rationale determines the valuation.
What evidence would make that acquisition financially rational?
Not what evidence would impress a scientific audience. What evidence would move the rNPV calculation past the threshold at which a deal becomes rational for the specific acquirer you have named.
If the answers to these three questions are vague, the equity story is not ready. The deck is not the problem. The architecture underneath it is.
Building backwards from the buyer
The practical implication of understanding pharma's decision criteria is that development strategy should be built backwards from the acquisition, not forwards from the laboratory.
Start with the five threshold conditions. For each one, ask where your asset currently stands and what it would take to move from current status to threshold. That exercise produces a ranked list of development priorities that is grounded in the buyer's decision framework rather than the founder's scientific interests.
It also produces something more valuable: a coherent answer to the question every investor eventually asks. Not "what is your drug?" But "who buys this, and why, and when, and for how much?"
That answer, stated precisely and defended with evidence, is the equity story. Everything else is detail.
Leonardo Biondi works with biotech founders and technology transfer offices to build the investment architecture that sits underneath the pitch deck. If you want to map your asset against pharma's decision criteria before your next investor conversation, book a 30-minute call.